{"id":"q-laiv-medi3250","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasal congestion"},{"rate":null,"effect":"Runny nose"},{"rate":null,"effect":"Sore throat"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Q/LAIV uses a live but weakened influenza virus that replicates in the nasal mucosa to stimulate both mucosal and systemic immune responses. The vaccine is designed with a cold-adapted, temperature-sensitive master donor virus backbone combined with surface antigens from circulating seasonal influenza strains, allowing it to induce protective immunity while minimizing systemic reactogenicity.","oneSentence":"Q/LAIV is a live attenuated influenza vaccine (LAIV) engineered with a reassortant backbone to provide broad protection against seasonal influenza strains.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:30:53.198Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in pediatric and adult populations"}]},"trialDetails":[{"nctId":"NCT00860067","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-03","conditions":"Healthy or Stable Underlying Chronic Medical Condition","enrollment":1800},{"nctId":"NCT01091246","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2010-03","conditions":"Healthy or Stable Chronic Illness","enrollment":2312}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MEDI3250"],"phase":"phase_3","status":"active","brandName":"Q/LAIV (MEDI3250)","genericName":"Q/LAIV (MEDI3250)","companyName":"MedImmune LLC","companyId":"medimmune-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Q/LAIV is a live attenuated influenza vaccine (LAIV) engineered with a reassortant backbone to provide broad protection against seasonal influenza strains. Used for Seasonal influenza prevention in pediatric and adult populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}